In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tyco, CR Bard to merge; deal terminated

Executive Summary

Tyco International had planned to acquire CR Bard (vascular, urological, and oncological diagnosis and intervention products) in a stock swap worth about $3.2bn, including the assumption of debt. However, since Tyco announced it will split into four independent companies, CR Bard and Tyco have mutually agreed to terminate their merger agreement. No break-up fees will be incurred.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies